Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22412949 | 0.98 | CA2 (0.41) | CA2SHBGAPPEGFRSRC | |
| SCHEMBL307532 | 0.80 | EGFR (0.47) | CA2SHBGAPPEGFRSRC | |
| SCHEMBL12259387 | 0.78 | PRKDC (0.44) | EGFRSRCKDM4EALDH1A1MAPT | |
| SCHEMBL31322320 | 0.77 | ALOX5 (0.57) | CA2RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL14137597 | 0.77 | ALOX5 (0.57) | CA2RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL20468570 | 0.76 | L3MBTL1 (0.66) | SHBGAPPRAB9AMAPTUSP2 | |
| SCHEMBL22426083 | 0.76 | CA2 (0.40) | CA2SHBGAPPEGFRSRC | |
| SCHEMBL4143009 | 0.75 | MAOB (0.62) | CA2SHBGAPPEGFRSRC | |
| Iodide SCHEMBL28186973 | 0.75 | ALOX5 (0.54) | CA2RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL20208913 | 0.73 | ALOX5 (0.57) | CA2APPRAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445702-B2 | Zinc binding compounds and their method of use | Life Technologies Corporation (US) | 2013-05-21 | — | — | US | claimed |
| US-20110159517-A1 | Zinc binding compounds and their method of use | Life Technologies Corporation (US) | 2011-06-30 | — | — | US | claimed |
| US-20090181364-A1 | ZINC BINDING COMPOUNDS AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-07-16 | — | — | US | claimed |
| US-20050250214-A1 | Zinc binding compounds and their method of use | MOLECULAR PROBES, INC. | 2005-11-10 | — | — | US | claimed |
| US-6962992-B2 | Crown ether derivatives for use in enhancing transfer of indicators into viabile cells | MOLECULLAR PROBES, INC. (US) | 2005-11-08 | — | — | US | claimed |
| US-20020164616-A1 | Crown ether derivatives | MOLECULAR PROBES, INC. (US) | 2002-11-07 | — | — | US | claimed |
| US-12487180-B2 | Device and methods for quantifying analytes introduction | Life Technologies Corporation (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4633458-A1 | SYSTEMS AND METHODS FOR ANALYTE DETECTION | Adaptyx Biosciences, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4565237-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | Chimerix, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119997956-A | Pharmaceutical composition and use thereof for treating glioma | 奇默里克斯公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250120620-A1 | SYSTEMS AND METHODS FOR ANALYTE DETECTION | Adaptyx Biosciences, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4524567-A2 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | Oncoceutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2004042347-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040096978-A1 | Crown ether derivatives | MOLECULAR PROBES, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040038306-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2004-02-26 | — | — | US | disclosed |
| EP-0966458-B1 | SULFONATED XANTHENE DERIVATIVES | MOLECULAR PROBES INC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2003030817-A2 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20020164616-A1 | Crown ether derivatives | MOLECULAR PROBES, INC. (US) | 2002-11-07 | — | — | US | disclosed |
| US-6130101-A | FLUORESCENT PROBES FOR USE IN BIOLOGICAL SAMPLES | MOLECULAR PROBES, INC. (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159517-A1 | Zinc binding compounds and their method of use | SLC30A6, SLC30A7, SLC39A11 | CA2 23/4885SHBG 1029/4885APP 927/4885 |
| US-20050250214-A1 | Zinc binding compounds and their method of use | SLC30A6, SLC30A7, SLC39A11 | CA2 20/4885SHBG 1042/4885APP 997/4885 |
| US-20020164616-A1 | Crown ether derivatives | CD2, SLC40A1, NCOA1 | CA2 208/4885SHBG 1868/4885APP 4723/4885 |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | GRM3, HRH3, HTR2A | CA2 4377/4885SHBG 2834/4885APP 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.